Camurus Interim Report January-March 2019
”Initial sales of Buvidal® follows plan and we are expecting to see significant growth during the year” Summary first quarter 2019 · Buvidal® launched as the first long-acting medicine for opioid dependence in the EU; with initial sales in Finland, the UK, Sweden, Germany and Denmark · Net revenues amounted to MSEK 18.5 (14.6), of which MSEK 11.0 (3.0) were from product sales · Enrollment completed in the DEBUT clinical study, comparing Buvidal® with daily treatment with sublingual buprenorphine/naloxone · Last patient last visit in the Phase 3 long-term extension